Navigation Links
Trading Of Onyx Pharmaceuticals Common Stock Halted
Date:6/20/2012

SOUTH SAN FRANCISCO, Calif., June 20, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that NASDAQ has halted trading of the company's common stock.   The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this afternoon to discuss the company's New Drug Application (NDA) for Kyprolis™ (proposed brand name for carfilzomib) under the accelerated approval pathway.

The NDA for Kyprolis for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies that included a proteasome inhibitor and an immunomodulatory agent is currently being reviewed by the U.S. FDA, and the anticipated date for completion of review under the PDUFA guidelines is July 27, 2012.

Conference Call Today
The Onyx management team will host a webcast and conference call to discuss the ODAC recommendation today at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time).

To access a live audio webcast of the conference call, log onto the company's website at: http://www.onyx.com/investors/event-calendar.

To access the live conference call, dial (847) 585-4405 and use the passcode 32594605. A replay of the call will be available on the Onyx website or by dialing (630) 652-3042 and using the passcode 3259 4605# approximately two hours after the conference call concludes through July 4, 2012.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
2. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
7. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
10. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
11. Valeant Pharmaceuticals To Host Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Rich Pharmaceuticals, ... today announced a 1-for-100 reverse split of its issued ... opening of trading on Thursday, February 11, 2016. The ... under new CUSIP number 76303T308 and temporary ticker symbol ... commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... ALS Association, in partnership with ALS Finding a Cure, is ... to track TDP43 aggregation. The successful team(s) with the most ... --> --> ALS ... the brain and the spinal cord. Eventually, people with ALS ... often leads to total paralysis and death within two to ...
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging Inc. ... Ltd. (ASX: PME), has announced that the American College ... (UF) have selected the Visage 7 Enterprise Imaging ... the Emergent/Critical Care Imaging SIMulation (SIM). SIM is ... Imaging Program (WIDI), a multi-faceted and fully-integrated online ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... Boston, MA (PRWEB) , ... February 10, 2016 , ... ... light switch, and brings pain that is often severe, with intense swelling and redness. ... more than eight million people, but older adults are the most susceptible, according to ...
(Date:2/10/2016)... ... 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain ... Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... date is March 16, 2016. A free review copy is available to the ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | Ticket ... Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation , ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South Youth ... Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening session ... FHU and the creator of GO! Camp, has been named director. Gayle McDonald, currently ...
Breaking Medicine News(10 mins):